The quest to develop anti-CRC interventionsspurred us to embark on a drug discovery program to design structuraltemplates that can simultaneously inhibit HDAC isoforms and LSD1.It is noteworthy that the HDAC inhibitory template, owing to its structuralplasticity, has been a precursor for numerous bifunctional chemicalarchitectures. This evidence concerns the gene HDAC9 and colorectal carcinoma.